Investigating a medication to protect kidney function in heart transplant patients
Randomized Trial of Sodium-glucose cotransporter-2 Inhibition(SGLT2i) in Heart Transplant Recipients
This study is looking at whether a medication called empagliflozin can help improve kidney health and overall well-being in heart transplant patients who are at risk for kidney and heart problems, and we're inviting Veterans to join us in this important research.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Salt Lake City Healthcare System NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11048998 on NIH RePORTER |
What this research studies
This research focuses on heart transplant recipients who are at high risk for kidney and cardiovascular diseases due to preexisting conditions and the immunosuppressive therapies they require. The study will evaluate the effects of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), compared to a placebo over one year. By enrolling Veterans from six national referral centers, the research aims to determine if this medication can reduce kidney dysfunction and improve overall health outcomes in these patients. Participants will be monitored for changes in kidney function, specifically looking at albumin levels and glomerular filtration rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are Veterans who have undergone heart transplantation and are experiencing kidney dysfunction or are at risk for kidney disease.
Not a fit: Patients who have not undergone heart transplantation or those without kidney dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney health and reduced cardiovascular risks for heart transplant recipients.
How similar studies have performed: Previous studies have shown that SGLT2 inhibitors can provide significant kidney and cardiovascular benefits in other populations, suggesting potential for success in this novel application.
Where this research is happening
Salt Lake City, United States
- VA Salt Lake City Healthcare System — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Stehlik, Josef — VA Salt Lake City Healthcare System
- Study coordinator: Stehlik, Josef
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.